Sigyn Therapeutics (OTCMKTS:SIGY) Releases Earnings Results

Sigyn Therapeutics (OTCMKTS:SIGY) announced its quarterly earnings data on Tuesday. The company reported ($0.42) earnings per share for the quarter, Zacks reports.

Sigyn Therapeutics Price Performance

SIGY stock remained flat at $3.53 during midday trading on Tuesday. Sigyn Therapeutics has a twelve month low of $3.15 and a twelve month high of $6.34. The business has a 50 day moving average of $3.92 and a 200-day moving average of $4.03. The company has a market capitalization of $5.67 million, a price-to-earnings ratio of -0.74 and a beta of -1.04.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats.